Denali Therapeutics Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
11.71 |
22.24 |
105.72 |
246.61 |
491.06 |
718.62 |
| Przychód Δ r/r |
0.00% |
89.95% |
375.36% |
133.27% |
99.12% |
46.34% |
| Przychód (min) |
10.74 |
1.02 |
9.56 |
246.60 |
37.49 |
54.86 |
| Przychód (max) |
13.42 |
57.17 |
284.17 |
246.63 |
1,301.74 |
1,905.01 |
| EBITDA (średnia) |
-3.18 |
-6.04 |
-28.71 |
-66.96 |
-133.34 |
-195.13 |
| EBIT (średnia) |
-3.34 |
-6.35 |
-30.16 |
-70.37 |
-140.11 |
-205.04 |
| EBIT % |
-28.53% |
-28.53% |
-28.53% |
-28.53% |
-28.53% |
-28.53% |
| Zysk netto (średni) |
-453.94 |
-501.08 |
-503.31 |
-446.30 |
-174.02 |
6.14 |
| Zysk netto % |
-3877.06% |
-2253.07% |
-476.07% |
-180.97% |
-35.44% |
0.85% |
| EPS (średnia) |
-2.78 |
-3.05 |
-2.76 |
-2.22 |
-1.06 |
0.04 |
| Liczba analityków (Przychody) |
12 |
13 |
18 |
13 |
8 |
12 |
| Liczba analityków (EPS) |
14 |
14 |
15 |
12 |
7 |
10 |
| symbol |
DNLI |
DNLI |
DNLI |
DNLI |
DNLI |
DNLI |